Finally, analysis of The Cancer Genome Atlas Program (TCGA) data reveals that the TKI-increased and GC-blocked ligands signature can predict an adverse prognosis in EGFR active mutant lung adenocarcinoma patients, who would be treated with EGFR TKIs (Fig. 7g). Here, EGFR is linked to lung adenocarcinoma.